c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Se han encontrado 144 productos de "c-Met / HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Merestinib dihydrochloride
CAS:Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Fórmula:C30H24Cl2F2N6O3Forma y color:SolidPeso molecular:625.45Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Fórmula:C23H19N3O2Pureza:98% - 99.41%Forma y color:SolidPeso molecular:369.42NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Fórmula:C31H23F2N5O3Pureza:98.48%Forma y color:SolidPeso molecular:551.54Ref: TM-T6907
1mg34,00€2mg46,00€5mg66,00€10mg92,00€25mg167,00€50mg245,00€100mg356,00€200mg530,00€1mL*10mM (DMSO)82,00€CEP-40783
CAS:CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
Fórmula:C31H26F2N4O6Pureza:99.76% - 99.84%Forma y color:SolidPeso molecular:588.56Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C38H37FN4O8SPureza:99.93%Forma y color:SolidPeso molecular:728.79Crizotinib
CAS:Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Fórmula:C21H22Cl2FN5OPureza:99% - 99.87%Forma y color:SolidPeso molecular:450.34Ref: TM-T1661
2mgA consultar5mg33,00€10mg49,00€25mg55,00€50mg64,00€100mg88,00€500mg147,00€1mL*10mM (DMSO)50,00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Fórmula:C22H17N5O2Pureza:98.56%Forma y color:SolidPeso molecular:383.4S49076
CAS:S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Fórmula:C22H22N4O4SPureza:95.35% - 97.4%Forma y color:SolidPeso molecular:438.5Ref: TM-T3274
1mg34,00€2mg44,00€5mg58,00€10mg93,00€25mg167,00€50mg260,00€100mg432,00€200mg618,00€1mL*10mM (DMSO)64,00€DS-1205
CAS:DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Fórmula:C41H42FN5O7Pureza:99.75%Forma y color:SolidPeso molecular:735.8Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Fórmula:C23H19Cl2FN6OPureza:98.80%Forma y color:SolidPeso molecular:485.34Ref: TM-T4260
2mg34,00€5mg49,00€10mg64,00€25mg84,00€50mg92,00€100mg126,00€500mg303,00€1mL*10mM (DMSO)58,00€SGX-523
CAS:SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
Fórmula:C18H13N7SPureza:99% - >99.99%Forma y color:SolidPeso molecular:359.41BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Forma y color:SolidPeso molecular:468.84Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Fórmula:C28H27FN4O7S2Pureza:98.91%Forma y color:SolidPeso molecular:614.67XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Fórmula:C29H25FN4O5Pureza:98.60%Forma y color:SolidPeso molecular:528.53Crizotinib hydrochloride
CAS:Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Fórmula:C21H23Cl3FN5OPureza:98.73% - 98.87%Forma y color:SolidPeso molecular:486.8Ref: TM-T8399
5mg34,00€10mg50,00€25mg78,00€50mg94,00€100mg131,00€200mg162,00€500mg215,00€1mL*10mM (DMSO)56,00€BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Fórmula:C25H16F2N4O3Pureza:98.33%Forma y color:SolidPeso molecular:458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€1mL*10mM (DMSO)170,00€Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Fórmula:C34H40F2N4O14P2Forma y color:SolidPeso molecular:828.65Amuvatinib
CAS:Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.Fórmula:C23H21N5O3SPureza:99.38% - >99.99%Forma y color:SolidPeso molecular:447.51PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Fórmula:C32H34Cl2N4O4SPureza:97.05% - 98.82%Forma y color:SolidPeso molecular:641.61Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H17FN6OPureza:99.24%Forma y color:SolidPeso molecular:412.42Ref: TM-T1963
5mg48,00€10mg63,00€25mg78,00€50mg90,00€100mg124,00€200mg158,00€500mg255,00€1mL*10mM (DMSO)50,00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Fórmula:C19H16N8OPureza:98.41% - 98.55%Forma y color:SolidPeso molecular:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Fórmula:C25H23FN8O2S2·HClPureza:97.95%Forma y color:SolidPeso molecular:587Ref: TM-T5677
1mg35,00€5mg57,00€10mg95,00€25mg178,00€50mg264,00€100mg374,00€200mg537,00€1mL*10mM (DMSO)96,00€S49076 HCl
CAS:S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Fórmula:C22H18ClN3O5Pureza:98%Forma y color:SolidPeso molecular:439.85JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Fórmula:C19H13F2N7Pureza:97.15% - 98.61%Forma y color:SolidPeso molecular:377.35SGI-7079
CAS:SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.Fórmula:C26H26FN7Pureza:95.51% - 99.26%Forma y color:SolidPeso molecular:455.53Ref: TM-T6982
2mg39,00€5mg58,00€10mg92,00€25mg178,00€50mg230,00€100mg334,00€500mg782,00€1mL*10mM (DMSO)64,00€RPI-1
CAS:RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.Fórmula:C17H15NO4Pureza:98.91% - ≥95%Forma y color:SolidPeso molecular:297.31Merestinib
CAS:Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Fórmula:C30H22F2N6O3Pureza:95% - 99.71%Forma y color:SolidPeso molecular:552.53Ref: TM-T3455
1mg50,00€2mg66,00€5mg100,00€10mg137,00€25mg240,00€50mg403,00€100mg573,00€500mg1.198,00€1mL*10mM (DMSO)119,00€MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Forma y color:SolidPeso molecular:517.6Ref: TM-T6351
2mg35,00€5mg52,00€10mg85,00€25mg164,00€50mg255,00€100mgA consultar1mL*10mM (DMSO)62,00€Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Fórmula:C17H15N9Pureza:98.12%Forma y color:SolidPeso molecular:345.36Ref: TM-TQ0210
1mg47,00€2mg60,00€5mg96,00€10mg124,00€25mg200,00€50mg353,00€100mg537,00€1mL*10mM (DMSO)92,00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Fórmula:C23H18ClFN6OPureza:98.62% - 99.81%Forma y color:SolidPeso molecular:448.89SRI 31215 TFA
CAS:SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Fórmula:C27H34F3N5O3Pureza:98.25% - 99.97%Forma y color:SolidPeso molecular:533.6Ref: TM-T5478
1mg40,00€5mg92,00€10mg128,00€25mg248,00€50mg370,00€100mg527,00€200mg713,00€1mL*10mM (DMSO)96,00€Cabozantinib
CAS:Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).
Fórmula:C28H24FN3O5Pureza:99.68% - 99.88%Forma y color:SolidPeso molecular:501.51(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFórmula:C15H14N2OPureza:98.82% - ≥95%Forma y color:SolidPeso molecular:238.28Ref: TM-T2496
10mg35,00€25mg52,00€50mg79,00€100mg111,00€200mg168,00€500mg330,00€1mL*10mM (DMSO)44,00€Cabozantinib hydrochloride
CAS:Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Fórmula:C28H25ClFN3O5Pureza:99.97%Forma y color:SolidPeso molecular:537.96Ref: TM-T5164
1mg42,00€2mg52,00€5mg65,00€10mg92,00€25mg160,00€50mg235,00€100mg330,00€200mg538,00€500mg860,00€BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFórmula:C17H15N5Pureza:98.98%Forma y color:SolidPeso molecular:289.33Ref: TM-T7900
1mg35,00€5mg71,00€10mg112,00€25mg203,00€50mg294,00€100mg411,00€200mg553,00€1mL*10mM (DMSO)84,00€Afatinib
CAS:Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Forma y color:Off-White SolidPeso molecular:485.94Ref: TM-T21312
5mg34,00€10mg49,00€25mg81,00€50mg109,00€100mg137,00€200mg168,00€500mg284,00€1mL*10mM (DMSO)50,00€Amivantamab (Anti-c-MET)
CAS:Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Pureza:97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Forma y color:LiquidPeso molecular:145.88 kDaBafisontamab
CAS:Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Forma y color:LiquidDavutamig
CAS:Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Pureza:98%Forma y color:LiquidFiclatuzumab
CAS:Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.Pureza:95%Forma y color:LiquidPeso molecular:145.39 kDaMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFórmula:C20H11Cl2N3OPureza:98%Forma y color:SolidPeso molecular:380.23BMS-754807
CAS:BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Fórmula:C23H24FN9OPureza:99.69% - 99.94%Forma y color:SolidPeso molecular:461.49Ref: TM-T2349
1mg50,00€2mg66,00€5mg90,00€10mg158,00€25mg310,00€50mg509,00€100mg732,00€1mL*10mM (DMSO)110,00€AMG-458
CAS:AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Forma y color:SolidPeso molecular:539.58SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Fórmula:C28H30ClN5O4SPureza:98.62% - 99.53%Forma y color:Orange PowderPeso molecular:568.09Ref: TM-T6154
1mg44,00€2mg56,00€5mg92,00€10mg142,00€25mg268,00€50mg442,00€100mg652,00€1mL*10mM (DMSO)142,00€T-1840383
CAS:T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.Fórmula:C30H25ClFN5O4Forma y color:SolidPeso molecular:574c-Met-IN-13
CAS:c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.Fórmula:C30H28F2N2O6Forma y color:SolidPeso molecular:550.55c-Met-IN-12
CAS:c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.Fórmula:C34H29FN4O4Forma y color:SolidPeso molecular:576.62(R)-Afatinib
CAS:(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.Fórmula:C24H25ClFN5O3Forma y color:SolidPeso molecular:485.94Dalmelitinib
CAS:Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.Fórmula:C22H16FN7O2SForma y color:SolidPeso molecular:461.47MK-8033 hydrochloride
CAS:MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.Fórmula:C25H22ClN5O3SForma y color:SolidPeso molecular:507.99
